DRDO to launch 2DG medicine for treating Covid-19 patients next week

Topics DRDO | Coronavirus | Corona Remedies

Representative Image

The first batch of 10,000 doses of 2DG medicine for treating COVID-19 patients would be launched early next week, informed Defence Research and Development Organisation officials on Friday.

The official informed, "The first batch of 10,000 doses of 2DG medicine for the treatment of COVID-19 infected patients would be launched early next week and will be given to patients."

"The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt", informed DRDO officials.

Yesterday, Karnataka Health Minister Dr K Sudhakar visited DRDO campus.DRDO scientists briefed Minister about the 2-DG drug which could be a game-changer in the COVID-19 battle.

"Dr K Sudhakar was briefed by scientists about the ongoing efforts at the premier research organisation to find solutions to tackle the pandemic. This comes a day after the Minister's interaction with another premier science institute, the IISc", informed a release by the state government.

The 2-DG drug developed by DRDO is a big break-through and could be a game-changer in the battle against the pandemic as it helps in faster recovery of the hospitalised patients and reduces oxygen dependence. PM-CARES fund will procure 1.5 lakh units of Oxycare System at a cost of Rs 322.5 crore.

Another innovative solution, the Oxycare system reduces the workload and exposure of healthcare providers by eliminating the need of routine measurement and manual adjustments of Oxygen flow.

2-DG drug: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.

OxyCare System is a comprehensive system developed by DRDO to regulate oxygen being administrated to patients based on the sensed values of their SpO2 levels.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel